Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Prebet

Showing results (31-40 of 99) with videos related to

Pageof 10
Sort By:
Advances in Therapy|September 6, 2024
Healthcare Utilization and Costs Among Patients with Acute Myeloid Leukemia Receiving Oral Azacitidine Maintenance Therapy Versus No Maintenance: A US Claims Database StudyUma Borate, Karen Seiter, Ravi Potluri, et al.
Leukemia & Lymphoma|November 28, 2024
Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemiaAlice Mims, Zhuoer Xie, Ravi Potluri, et al.
American Journal of Hematology|March 6, 2014
Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemiaNathalie Cervera, Raphael Itzykson, Emilie Coppin, et al.
Leukemia & Lymphoma|December 3, 2016
Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemiaNorbert Vey, Thomas Prebet, Claire Thalamas, et al.
Oncotarget|June 17, 2014
Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALLMarie Loosveld, Rémy Castellano, Stéphanie Gon, et al.
Leukemia & Lymphoma|December 16, 2020
High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasisJennifer Zhao, Jan Philipp Bewersdorf, Sara Jaszczur, et al.
Blood|September 25, 2012
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remissionNorbert Vey, Jean-Henri Bourhis, Nicolas Boissel, et al.
Leukemia & Lymphoma|October 23, 2012
Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemiaRaynier Devillier, Roberto Crocchiolo, Anne Etienne, et al.
Annals of Hematology|February 2, 2023
Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United StatesAmer M Zeidan, Daniel A Pollyea, Uma Borate, et al.
Oncotarget|February 11, 2017
Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapyThomas Prebet, Andrea Toma, Thomas Cluzeau, et al.
Pageof 10

Showing results (31-40 of 99) with videos related to

Sort By:
Pageof 10
Advances in Therapy|September 6, 2024
Healthcare Utilization and Costs Among Patients with Acute Myeloid Leukemia Receiving Oral Azacitidine Maintenance Therapy Versus No Maintenance: A US Claims Database StudyUma Borate, Karen Seiter, Ravi Potluri, et al.
Leukemia & Lymphoma|November 28, 2024
Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemiaAlice Mims, Zhuoer Xie, Ravi Potluri, et al.
American Journal of Hematology|March 6, 2014
Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemiaNathalie Cervera, Raphael Itzykson, Emilie Coppin, et al.
Leukemia & Lymphoma|December 3, 2016
Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemiaNorbert Vey, Thomas Prebet, Claire Thalamas, et al.
Oncotarget|June 17, 2014
Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALLMarie Loosveld, Rémy Castellano, Stéphanie Gon, et al.
Leukemia & Lymphoma|December 16, 2020
High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasisJennifer Zhao, Jan Philipp Bewersdorf, Sara Jaszczur, et al.
Blood|September 25, 2012
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remissionNorbert Vey, Jean-Henri Bourhis, Nicolas Boissel, et al.
Leukemia & Lymphoma|October 23, 2012
Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemiaRaynier Devillier, Roberto Crocchiolo, Anne Etienne, et al.
Annals of Hematology|February 2, 2023
Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United StatesAmer M Zeidan, Daniel A Pollyea, Uma Borate, et al.
Oncotarget|February 11, 2017
Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapyThomas Prebet, Andrea Toma, Thomas Cluzeau, et al.
Pageof 10